Insomnia

New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT

Retrieved on: 
Friday, February 16, 2024

New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:

Key Points: 
  • New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:
    2).
  • Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia.
  • Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in the treatment success.
  • Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish fatigue in patients.

Sunderstorm Introduces the Next Generation of Functional Gummies, KANHA FX, Formulated by Doctors for Targeted Effects

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Sunderstorm's award-winning edibles brand is proud to welcome KANHA FX, a new line of functional gummies that heralds groundbreaking advancements in precision, innovation and targeted effects. Formulated by doctors to help set your mood, KANHA FX launches with three fast-acting gummies: ENERGY, SLEEP and LOVE.

Key Points: 
  • LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Sunderstorm's award-winning edibles brand is proud to welcome KANHA FX, a new line of functional gummies that heralds groundbreaking advancements in precision, innovation and targeted effects.
  • Formulated by doctors to help set your mood, KANHA FX launches with three fast-acting gummies: ENERGY, SLEEP and LOVE.
  • "The scientific community knows more about cannabinoids, terpenes and entourage effects today than it has at any time in history," explains Cameron Clarke, CEO and Co-Founder of Sunderstorm.
  • "As the science advances, our products will follow suit, and that commitment helps make KANHA FX the driving force behind the next generation of functional gummies.

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
Wednesday, February 14, 2024

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Capstone Strategic Releases Results of 2024 State of the Market Survey

Retrieved on: 
Monday, February 12, 2024

VIENNA, Va., Feb. 12, 2024 /PRNewswire-PRWeb/ -- Near the end of 2023, Capstone Strategic, Inc., a Vienna, Virginia based consulting firm specializing in middle market Mergers and Acquisitions, reached out to nearly 700 current and former clients to collect their thoughts and opinions on the growth environment in their industry and how they felt about near-term growth prospects for their companies.

Key Points: 
  • 36% of the respondents were CEOs, with the rest consisting of C-suite executives, vice presidents, and managers.
  • 27% opted for "Financial Stability" as driving their outlook, while 24% chose "Market trends" and 16% selected "Innovation opportunities."
  • As a final question, survey recipients were asked, "What keeps you up at night concerning your business?"
  • Other reasons respondents stated for insomnia regarding their business were "Regulatory compliance" and "Market volatility."

Alpha Cognition Provides Business Update

Retrieved on: 
Monday, February 12, 2024

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update.

Key Points: 
  • Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update.
  • ALPHA-1062 has a Prescription Drug User Fee Act (“PDUFA”) date (drug approval date) in the U.S. for July 27, 2024.
  • Alpha Cognition’s commercialization strategy includes our initial commercial launch in LTC, followed by expansion to the Neurology segment once payer reimbursement has been established.
  • For other Alpha Cognition programs the Company will explore out-licensing our progranulin and Granulin Epithelin Motifs (“GEM”) programs.

Why it’s a bad idea to mix alcohol with some medications

Retrieved on: 
Monday, February 12, 2024

But you may not be aware that mixing certain medicines with alcohol can increase the effects and put you at risk.

Key Points: 
  • But you may not be aware that mixing certain medicines with alcohol can increase the effects and put you at risk.
  • When you mix alcohol with medicines, whether prescription or over-the-counter, the medicines can increase the effects of the alcohol or the alcohol can increase the side-effects of the drug.
  • This is because there is less water in their bodies that can mix with the alcohol.
  • If you do want to drink alcohol while being on medication, discuss it with your doctor or pharmacist first.

PHFA shares progress made on PAHAF assistance to homeowners in January

Retrieved on: 
Friday, February 9, 2024

HARRISBURG, Pa., Feb. 9, 2024 /PRNewswire/ -- The Pennsylvania Housing Finance Agency today is providing an update on the steady progress being made by the Pennsylvania Homeowner Assistance Fund to assist people whose lives were disrupted by the pandemic.

Key Points: 
  • During the month of January, the PAHAF program has disbursed an additional $10.7 million of funding to homeowners in need of pandemic-related assistance.
  • PAHAF assistance is being used to provide mortgage reinstatement, forward mortgage payments, property charges and unpaid utility bills.
  • Funds are being distributed directly to mortgage lenders, servicers, utility providers and other authorized third parties, not to homeowners.
  • PHFA remains fully committed to quickly and responsibly disburse all PAHAF financial assistance to Pennsylvania homeowners, as evidenced by its improvement of the program's management.

Why are so many Australians taking antidepressants?

Retrieved on: 
Thursday, February 8, 2024

Around one in seven Australians take antidepressants; more than 3.5 million of us had them dispensed in 2021–22.

Key Points: 
  • Around one in seven Australians take antidepressants; more than 3.5 million of us had them dispensed in 2021–22.
  • Guidelines mostly recommend antidepressants for more severe depression and anxiety but not as first-line treatment for less severe depression.
  • So why are so many Australians taking antidepressants and why are prescriptions rising?

Enter the antidepressant ‘blockbusters’

  • In the 1990s, pharmaceutical companies heavily promoted new selective serotonin reuptake inhibitors (SSRI) antidepressants, including Prozac (fluoxetine), Zoloft (sertraline) and Lexapro (escitalopram).
  • These drugs were thought to be less dangerous in overdoses and seemed to have fewer side effects than the tricyclic antidepressants they replaced.
  • Pharmaceutical companies marketed SSRIs energetically and often exaggerated their benefits, including by paying “key opinion leaders” – high-status clinicians to promote them.

Why are antidepressants prescribed?

  • GPs also prescribe antidepressants to patients experiencing distress but who don’t have a psychiatric diagnosis.
  • Another, who cried when informed she had breast cancer, was immediately offered a prescription for antidepressants.
  • Most patients believe antidepressants restore a chemical imbalance that underpins depression.
  • Antidepressants are emotional (and sexual) numbing agents – sometimes sedating, sometimes energising.
  • Around half of users have impaired sexual function and for some, this sexual dysfunction persists after stopping antidepressants.

How long do people take antidepressants?

  • Around half of patients who start antidepressants don’t like them and stop within weeks.
  • Of those who do take them for months, many continue to use them indefinitely, often for many years.
  • Read more:
    Antidepressants can cause withdrawal symptoms – here’s what you need to know

We need to adjust how we view mental distress

  • Overprescribing antidepressants is a symptom of our lack of attention to the social determinants of mental health.
  • GPs also need to ensure they discuss with their patients the potential adverse effects of antidepressants, and when and how to safely stop them.
  • But the fundamental problem is social and can only be properly addressed by meaningfully addressing inequality and changing community attitudes to distress.


Jon Jureidini receives research funding from MMRF. He is affiliated with Critical Psychiatry Network Australasia.

Nox Health Appoints Jonathan Fox as Chief Commercial Officer of its Enterprise Business

Retrieved on: 
Wednesday, February 7, 2024

ALPHARETTA, Ga., Feb. 7, 2024 /PRNewswire/ -- Nox Health, a global leader in sleep diagnostics and value-based sleep care management, today announced the appointment of Jonathan Fox as Chief Commercial Officer of its Enterprise business. In this role, Jonathan will focus on expanding Nox Health's value-based sleep care management business in the U.S. benefits space, reframing sleep as a critical intervention strategy for chronic conditions.

Key Points: 
  • ALPHARETTA, Ga., Feb. 7, 2024 /PRNewswire/ -- Nox Health , a global leader in sleep diagnostics and value-based sleep care management, today announced the appointment of Jonathan Fox as Chief Commercial Officer of its Enterprise business.
  • In this role, Jonathan will focus on expanding Nox Health's value-based sleep care management business in the U.S. benefits space, reframing sleep as a critical intervention strategy for chronic conditions.
  • His exceptional domain expertise and leadership capabilities will be an invaluable asset to Nox," said Sigurjon Kristjansson, CEO of Nox Health.
  • "Sleep is usually a missing but foundational gap in care, inextricably linked to the chronic conditions which drive plan sponsor and health plan costs," noted Jonathan Fox, Chief Commercial Officer of the Nox Health Enterprise business.